Genenta Science Offers Update on TEM-GBM Research Study

Study Update: Genenta Science's TEM-GBM study shows that 44% of newly diagnosed glioblastoma multiforme patients with an unmethylated MGMT gene promoter have reached 18-month survival, an increase from 38% reported in April. The two-year survival rate remains at 29%, with a median overall survival of 17 months.

Long-term Survival Case: The study includes a patient who has survived three years after Temferon treatment without additional therapies, although disease progression was noted at the follow-up visit. This patient is one of two in the study who did not require further interventions during the follow-up period.

Immune Observations: Preliminary findings suggest that bone-marrow-derived myeloid cells can effectively deliver immunotherapeutic payloads to the tumor site, aligning with the intended design of the Temferon platform.

Future Implications: These exploratory observations are helping to inform the broader development of Temferon, including potential combination therapies and advancements in cell-based delivery technology, although further confirmation in larger studies is needed.